BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20197401)

  • 1. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
    Meng XW; Lee SH; Dai H; Loegering D; Yu C; Flatten K; Schneider P; Dai NT; Kumar SK; Smith BD; Karp JE; Adjei AA; Kaufmann SH
    J Biol Chem; 2007 Oct; 282(41):29831-46. PubMed ID: 17698840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Okumura K; Sinicrope FA
    Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
    Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
    Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
    Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
    Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
    Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
    Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
    Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund AC; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
    Cell Death Dis; 2012 Jan; 3(1):e262. PubMed ID: 22278289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
    Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
    Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
    Kiprianova I; Remy J; Milosch N; Mohrenz IV; Seifert V; Aigner A; Kögel D
    Neoplasia; 2015 Jul; 17(7):564-73. PubMed ID: 26297434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
    Gillissen B; Richter A; Richter A; Preissner R; Schulze-Osthoff K; Essmann F; Daniel PT
    J Biol Chem; 2017 Apr; 292(16):6478-6492. PubMed ID: 28154184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
    Rahmani M; Davis EM; Bauer C; Dent P; Grant S
    J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
    Zhao W; Zhang T; Qu B; Wu X; Zhu X; Meng F; Gu Y; Shu Y; Shen Y; Sun Y; Xu Q
    Anticancer Drugs; 2011 Jan; 22(1):79-88. PubMed ID: 20881478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
    Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
    Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
    Ricci MS; Kim SH; Ogi K; Plastaras JP; Ling J; Wang W; Jin Z; Liu YY; Dicker DT; Chiao PJ; Flaherty KT; Smith CD; El-Deiry WS
    Cancer Cell; 2007 Jul; 12(1):66-80. PubMed ID: 17613437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor MG132 potentiates TRAIL receptor agonist-induced apoptosis by stabilizing tBid and Bik in human head and neck squamous cell carcinoma cells.
    Sung ES; Park KJ; Choi HJ; Kim CH; Kim YS
    Exp Cell Res; 2012 Aug; 318(13):1564-76. PubMed ID: 22513214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.